ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET FORECAST 2023-2032

The Asia-Pacific skin cancer diagnostics market growth analysis includes a thorough study of Australia & New Zealand, Vietnam, China, Indonesia, South Korea, Japan, Thailand, India, and Rest of Asia-Pacific. In China, melanoma has been a concerning rise in skin cancer over the past few decades. In 2017, the age-standardized incidence rate of melanoma was 9 per 100,000, reflecting a significant increase of 110.3% since 1990. The burden of melanoma on public health has also become apparent, as indicated by the disability-adjusted life-years (DALYs), which experienced a significant increase of 13.6% annually from 2007 to 2017, resulting in an age-standardized rate of 7.6 per 100,000 in 2017.

The economic impact of melanoma on patients in Hunan, China, is substantial, with median spending reaching nearly 60% of the average annual disposable income. Specifically, middle-aged men with melanoma on their limbs face the highest financial burden associated with the disease. Additionally, skin cancer has emerged as a pressing public health concern in China. Recent data from the World Health Organization (WHO) revealed that skin cancer deaths accounted for 19,669 or 0.20% of total deaths in China. Recognizing the issue’s significance, China has incorporated cancer prevention and control as a major special action in its ‘Healthy China Action (2019-2030)’ initiative.

Moreover, the demand for cancer care in China is evident, as cancer hospitals received over 22 million patient visits in 2020, albeit slightly lower than the previous year. Between 2010 and 2019, treatment visits steadily increased, with figures in 2019 tripling compared to 2010. As the incidence of skin cancer continues to rise, and new technologies and diagnostic tools become available, the skin cancer diagnostic market in China is projected to grow, providing healthcare providers and patients with improved capabilities in diagnosis and treatment. 

The Asia-Pacific skin cancer diagnostics market segmentation evaluation entails gender, type, and screening type. Market by type covers melanoma and non-melanoma.

Melanoma, a highly dangerous form of skin cancer, is characterized by its aggressive growth and ability to spread to any organ. Originating from melanocytes, the cells responsible for producing skin pigment, melanoma typically appears as black or brown but manifests in pink, red, purple, or skin-colored variations.

Although melanoma represents only 1% of all skin cancers, it accounts for most skin cancer-related deaths. It is particularly prevalent among individuals under 30, predominantly affecting young women. The incidence of melanoma has seen a significant increase over the past three decades, largely attributed to heightened exposure to ultraviolet (UV) radiation, a major contributing factor to the rise in cases.

Leading companies operating in the Asia-Pacific skin cancer diagnostics market include Michelson Diagnostics Ltd, AMLo Biosciences Limited, etc.

AMLo Biosciences Ltd is a company that operates in the Biotechnology industry. The company provides a prognostic test for detecting early AJCC Stage I and Stage II melanoma. The company’s product includes AMBLor, a diagnostic test based on two protein markers, AMBRA1 and loricrin (AMLo), in the upper epidermis layer. It is headquartered in Newcastle upon Tyne, United Kingdom.

AMBLor® from AMLo Biosciences Ltd is a development test based on two protein markers normally present in the upper layer of the skin (epidermis).